

Special Issue

Safety and Side Effects in SARS-CoV-2 Vaccine

Message from the Guest Editors

COVID-19 vaccines are important in the global battle against the SARS-CoV-2 pandemic. The swift development and distribution of COVID-19 vaccines, including mRNA (Pfizer-BioNTech, Moderna), viral vector (AstraZeneca, Johnson & Johnson, Sputnik V), and protein subunit (Novavax) vaccines, or inactivated virus (Sinovac, Sinopharm) vaccines, have been unprecedented. This Special Issue invites research papers and reviews that enhance current understanding of these vaccines' safety and side effects, focusing on special populations (e.g., the elderly and children, pregnant and lactating women, and immunocompromised individuals) and rare adverse events. Understanding these aspects is critical for healthcare providers and policymakers to improve vaccine confidence and optimize public health strategies. We also welcome articles on vaccine safety monitoring systems, e.g., the vaccine adverse event reporting system (VAERS) and the vaccine safety datalink (VSD). We look forward to receiving your research articles, including reviews.

Guest Editors

Dr. Ying-Fei Yang

Department of Bioenvironmental Systems Engineering, National Taiwan University, Taipei 10617, Taiwan

Dr. Sher Singh

Department of Life Science, School of Life Science, College of Science, National Taiwan Normal University, Taipei 11677, Taiwan

Deadline for manuscript submissions

30 November 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/207374

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).